MHRA (UK)
OTHER
MHRA Safety Roundup: March 2026
Published: 3/31/2026Detected: 5/5/2026
Summary preview
Provides a consolidated roundup of MHRA’s latest safety advice affecting how medicines and medical device users should interpret, act on, and escalate emerging safety information.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountsafety
labeling
clinical
quality
manufacturing
#MHRA safety advice
#pharmacovigilance
#post-market surveillance
#medical devices
#product information
Official Source Document Source Verified
Access the original document directly from MHRA.
More from MHRA (UK)
- Class 4 Medicines Defect Notification: Neuraxpharm UK Limited, Levetiracetam Neuraxpharm granules for oral solution in sachet, EL(26)A/4010/1/2026
- Field Safety Notices: 21 to 25 September 20269/29/2026
- MHRA Safety Roundup: September 20269/29/2026
- Class 4 Medicines Defect Notification: B. Braun Melsungen AG, Meropenem 1000 mg powder and solvent for solution for infusion, EL(26)A/399/23/2026
- Field Safety Notices: 14 to 18 September 20269/23/2026